Xiangxue Pharmaceutical (300147) — Cash Flow Reinvestment Rate
Xiangxue Pharmaceutical (300147) has a Cash Flow Reinvestment Rate of 0.08x as of September 2025, reinvesting CN¥5.74 Million (capex CN¥5.74 Million ) from operating cash flow of CN¥75.64 Million. Check how high is Xiangxue Pharmaceutical's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Xiangxue Pharmaceutical Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Xiangxue Pharmaceutical across 19 annual periods. Explore long-term investment intensity of Xiangxue Pharmaceutical to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Xiangxue Pharmaceutical (2007–2025)
Year-by-year capital reinvestment analysis for Xiangxue Pharmaceutical. For live market cap and broader valuation context, see 300147 company net worth.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.18x | CN¥25.47 Million | CN¥139.63 Million | CN¥21.51 Million | ▼ -94.4% |
| 2024 | 3.24x | CN¥58.95 Million | CN¥18.17 Million | CN¥35.24 Million | ▲ +678.9% |
| 2023 | 0.42x | CN¥109.69 Million | CN¥263.44 Million | CN¥56.03 Million | ▼ -77.7% |
| 2022 | 1.87x | CN¥425.18 Million | CN¥227.38 Million | CN¥367.27 Million | ▼ -21.2% |
| 2021 | 2.37x | CN¥611.43 Million | CN¥257.56 Million | CN¥562.74 Million | ▼ -15.2% |
| 2020 | 2.80x | CN¥719.65 Million | CN¥257.18 Million | CN¥707.42 Million | ▼ -77.3% |
| 2019 | 12.34x | CN¥1.02 Billion | CN¥83.02 Million | CN¥661.09 Million | ▲ +82.4% |
| 2018 | 6.76x | CN¥617.05 Million | CN¥91.24 Million | CN¥495.46 Million | ▼ -19.3% |
| 2017 | 8.38x | CN¥917.76 Million | CN¥109.53 Million | CN¥777.87 Million | ▼ -23.6% |
| 2016 | 10.97x | CN¥2.18 Billion | CN¥198.48 Million | CN¥1.97 Billion | ▲ +183.3% |
| 2015 | 3.87x | CN¥618.83 Million | CN¥159.89 Million | CN¥276.95 Million | ▲ +162.8% |
| 2014 | 1.47x | CN¥243.85 Million | CN¥165.58 Million | CN¥243.85 Million | ▲ +51.8% |
| 2013 | 0.97x | CN¥318.55 Million | CN¥328.37 Million | CN¥318.55 Million | ▼ -72.4% |
| 2012 | 3.52x | CN¥418.12 Million | CN¥118.91 Million | CN¥418.12 Million | ▼ -55.0% |
| 2011 | 7.81x | CN¥230.69 Million | CN¥29.55 Million | CN¥230.69 Million | ▲ +524.1% |
| 2010 | 1.25x | CN¥56.87 Million | CN¥45.47 Million | CN¥56.87 Million | ▲ +9.3% |
| 2009 | 1.14x | CN¥52.86 Million | CN¥46.19 Million | CN¥52.86 Million | ▼ -53.7% |
| 2008 | 2.47x | CN¥137.71 Million | CN¥55.72 Million | CN¥137.71 Million | ▲ +135.7% |
| 2007 | 1.05x | CN¥144.73 Million | CN¥138.02 Million | CN¥144.73 Million | — |